Navigation Links
GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America
Date:3/9/2011

its in a location convenient to them.

"GlobalCare continues to expand its network based on client demands, and Latin America has become one of the most prominent new clinical trials locations. The standard of medical training in Latin America is high and, due to improvements in the countries' regulatory legislation, investigators are knowledgeable in GCP/ICH guidelines. There are also large numbers of drug-naive subjects. Thus, it made sense to extend GlobalCare's services to this region, cost-effectively delivering high quality and flexible clinical trial services to patients in convenient settings like their home or office," said Gail Adinamis, founder and Chief Executive Officer of GlobalCare.

Reduction in subject recruitment time by over 50% and an increase in subject retention rate of over 95% are among the results that have spurred GlobalCare's rapid growth.

"As industry demand increases for accelerated patient enrollment and streamlined study processes on a global basis, we will continue to expand our network to facilitate the timely and successful completion of clinical trials across biopharmaceuticals while providing important return on investment for sponsors," Adinamis continued.

Therapeutic areas that tend to benefit the most from this model include, but are not limited to, oncology, neurology, infectious disease and the central nervous system. GlobalCare's services are also advantageous for the support of orphan drug studies, where patients typically live significant distances from investigative sites. And, GlobalCare employs an extensive screening and qualification process for its network members and maintains a rigorous quality management system to promote standardization globally while complying with all applicable regulations.

"In addition to our teamwork, quality and responsiveness, GlobalCare works with an unwavering commitment to patient care, safety and ethics," states Adinamis.

Leadership and Exper
'/>"/>

SOURCE GlobalCare Clinical Trials, Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Richmond, VA (PRWEB) November 21, 2014 ... businessman who understood the need to surround himself with ... visionary, CEO and entrepreneur, his friends often marveled at ... how he lived his life and -- even with ... cure for the Alzheimer’s disease that would ultimately take ...
(Date:11/22/2014)... 21, 2014 On November 17th Chicago ... 2014 Emerging Medical Technologies Summit in San Francisco to ... Widely regarded among Silicon Valley investors and technology elites ... the win also positions Briteseed to move on ... in 2015 and compete with other elite innovation finalists ...
(Date:11/22/2014)... , November 21, 2014   ... als Chief Commercial Officer zu KLOX    ... Unternehmensentwicklung und Chief Financial Officer bestellt    ... der Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu ... bzw. das "Unternehmen") ist sehr erfreut, die folgenden personellen ...
(Date:11/21/2014)... Offering a complete line of laboratory balances, ... . The Sartorius Entris Balance is the perfect laboratory ... easy-to-maintain balance entry level balance. , The Entris was ... help customer’s bridge the gap between a basic balance ... durable. Sartorius is the second biggest balance manufacturer in ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2
... The Netherlands, April 28 , ... Brachytherapy Represents the,Next Generation in DICOM-Compatible, ... a knowledge-based leader in radiation oncology, ... a comprehensive,volume-based treatment planning system to ...
... Simcere,Pharmaceutical Group (NYSE: SCR ), a leading ... of the patented,anti-cancer biotech product Endu in China, ... of its existing shareholders, New Good Management,Limited, a ... including certain senior management of Simcere Pharmaceutical,has entered ...
... on a Non-Exclusive Basis, Proprietary MicroRNAs ... Agreement, Rosetta Genomics has Access to a Full Range ... MicroRNA Applications Based on These MicroRNAs, REHOVOT, Israel ... (Nasdaq: ROSG ), a leading,developer of microRNA-based diagnostics ...
Cached Biology Technology:Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 2Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 3Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate 4
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
(Date:11/2/2014)... support of a bold quest to rid the world ... today announced an award of US$156 million to PATH ... building new vaccines that will interrupt the cycle of ... zero" agenda. Such vaccines would ensure that parasite reintroduction ... "immunological bed net." , This approach to developing ...
(Date:11/2/2014)... and bump into a biologist . . . , While ... sketch, researchers have taken this premise and applied it to ... in the rising oceans of genomic data. , In this ... studies are publishing at a dizzying rate. The challenge is ... the noise (and there is no shortage of noise). , ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... Institute of Allergy and Infectious Diseases (NIAID), part of ... powerful inhibitor of anthrax toxin that worked well in ... the design of anthrax antitoxin is an important advance, ... anthrax treatment, but also because this technique could be ...
... in North America, two types of invasive vines are ... butterfly populations and bird habitats. , The vines are ... control to stem the growth of and their steady ... and Canada, Cornell University is teaming up with the ...
... images of other monkeys glancing one way or the ... high-ranking monkeys, Duke University Medical Center neurobiologists have discovered. ... low-status monkeys; while low-status monkeys assiduously follow the gaze ... than a confirmation of what most people believe about ...
Cached Biology News:Scientists design potent anthrax toxin inhibitor 2Scientists design potent anthrax toxin inhibitor 3CU, USDA team to curb two invasive, poisonous vines 2CU, USDA team to curb two invasive, poisonous vines 3'Executive' monkeys influenced by other executives, not subordinates 2'Executive' monkeys influenced by other executives, not subordinates 3
... Luminometer has been designed,for the detection ... measurements of glow and flash luminescence ... light remain nearly constant,over a longer ... for very fast reactions,requiring at least ...
... than western blotting. Get results sooner and save ... gel detection. Eliminates the need for a membrane ... All reagents are ready-to-use. No reagents to prepare ... 2 reagents required. Guarantees a simple to perform, ...
... The EZ-Tn5™ Plasmid-Based Deletion Machine is ... vitro transposition system developed by Goryshin and ... generation of nested families of deletions and ... cloned in a transposon-containing plasmid vector. Although ...
... This kit is designed to knockout or alter ... less than one week. Red/ET recombination allows the ... precise, specific, and faithful manner. An FRT-flanked kanamycin ... which can be used to replace a gene ...
Biology Products: